1) Rizzo JD, Curtis RE, Socié G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009;113(5):1175-83.
2) Teepen JC, Van Leeuwen FE, Tissing WJ, et al;DCOG LATER Study Group. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER Study cohort:role of chemotherapy. J Clin Oncol 2017;35(20):2288-98.
3) Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47.
4) Socié G, Henry-Amar M, Devergie A, et al. Poor clinical outcome of patients developing malignant solid tumors after bone marrow transplantation for severe aplastic anemia. Leuk Lymphoma 1992;7(5-6):419-23.
5) Gladdy RA, Qin LX, Moraco N, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol 2010;28(12):2064-9.
6) 日本整形外科学会(監),日本整形外科学会診療ガイドライン委員会・軟部腫瘍診療ガイドライン策定委員会(編).軟部腫瘍診療ガイドライン2020.改訂第3版.東京:南江堂;2020.
7) Tanaka K, Kawano M, Iwasaki T, et al. A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas. PLoS One 2019;14(1):e0210671.
8) Fisher SB, Chiang YJ, Feig BW, et al. Comparative performance of the 7th and 8th editions of the American Joint Committee on Cancer staging systems for soft tissue sarcoma of the trunk and extremities. Ann Surg Oncol 2018;25(5):1126-32.